Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
The objective of this study is to deliver proof of concept that antifungal prophylaxis can
 reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit)
 patients with severe influenza.

 The investigators will perform an interventional non-blinded randomized controlled
 multicentric proof-of-concept study in patients with severe influenza admitted to the ICU.
 Patients will be randomized to the posaconazole prophylaxis group or to the SOC (standard of
 care) group. Oseltamivir will be started at the discretion of the investigator. Patients in
 the posaconazole group will receive posaconazole prophylaxis for 7 days.

 addendum: pharmacokinetics of posaconazole as prophylaxis for invasive fungal disease on ICU
Critically ill patients with PCR-confirmed influenza criteria) are eligible for inclusion in
 this study and will be randomized to or the posaconazole prophylaxis group or the SOC group.

 If a patient is randomized to the posaconazole prophylaxis group, posaconazole (Noxafil, MSD)
 will be started intravenously from day 1 of randomization (2*300mg( milligram) /d on day 1,
 followed by 1*300mg/d from day 2 for 7 days) In both patient groups (prophylaxis and SOC)
 oseltamivir (non-IMP) will be started at the discretion of the treating physician from the
 first day of ICU admission as 2*150 mg/day for 10 days. If oseltamivir had already been
 started up before ICU admission, oseltamivir treatment will be continued up to a total of 10
 days.

 Within 48 hours after influenza diagnosis a bronchoscopy with BAL (bronchoalveolar lavage)
 and a serum galactomannan will be performed as part of routine ICU care in this type of
 patients. If an IAA-infection is suspected based on the result of this BAL ((A) Aspergillus
 cultured from BAL, or (B) a galactomannan (GM)the patient will be withdrawn from the study
 and antifungal treatment will be started.

 addendum: Extensive PK sampling (UZ Leuven and Radboud): full PK curve on day 2 and day 5
 (predose, 1.5; 2,3,4,6,8,10,12,18,24 h post infusion).

 on non PK days, until day 7, predose sample. PK in BAL fluid only in patients with mechanical
 ventilation and when medically indicated.

 Limited PK sampling: on day 2 and day 5: 1.5-3h, 4-8 h;8-12h; 12-24h post dose. on non PK
 days: PK pre dose.
Inclusion Criteria:

 1. Written informed consent must be obtained from the patient or his/her legal
 representative prior to any study procedures

 2. Adult patient (≥ 18 years)

 3. PCR-confirmed influenza based on nasopharyngeal swab (NS), bronchial aspirate (BA) or
 broncho-alveolar lavage (BAL) within 7 days before ICU admission or within 48 hours
 after ICU admission. If PCR is not available a positive result of a rapid test is
 required (a negative rapid test does not imply absence of influenza and thus requires
 confirmation by PCR)

 4. Influenza symptoms present for no more than 10 days before ICU admission

 5. Respiratory distress as the main reason for ICU admission. Respiratory distress will
 be defined as tachypnea with an respiratory rate ≥ 25x/min and a paO2/fiO2-ratio
 (fraction of inspired oxygen) ≤ 300 with or without (bilateral) infiltrates.

 Exclusion Criteria:

 1. Patients with age < 18 years

 2. Pregnant women (based on a positive serum sample)

 3. Expected survival on ICU admission ≤ 48h

 4. Patients having influenza symptoms for more than 10 days before ICU admission

 5. Patients being transferred from another hospital ward or another hospital who already
 have mycological evidence for an IAA-infection (based on sputum, BA or BAL culture,
 BAL or serum GM)

 6. Patients with known intolerance or hypersensitivity to posaconazole or other azole
 antifungal agents

 7. Patients that are being treated actively with antifungal agents for invasive
 aspergillosis

 8. Patients with a QTc (corrected QT interval) interval ≥500 msec

 9. Patients with liver cirrhosis (Child C)

 10. Participation in another interventional clinical trial -